1. Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis
   B S Vinod et al, 2015, Cell Death Discovery CrossRef
2. Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
   Maria Gaibar et al, 2020, Journal of Oncology CrossRef
3. Theranostic Approach in Breast Cancer
   Narges Jokar et al, 2021, Clinical Nuclear Medicine CrossRef
4. Is Curcumin the Answer to Future Chemotherapy Cocktail?
   Wei-Yang Kong et al, 2021, Molecules CrossRef
5. AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion
   Jie Zhang et al, 2019, Disease Markers CrossRef
6. Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells
   Zh. K. Nazarkina et al, 2016, Bulletin of Experimental Biology and Medicine CrossRef
7. Cooperative oncogenic effect and cell signaling crosstalk of co-occurring HER2 and mutant PIK3CA in mammary epithelial cells
   Lun Dong et al, 2017, International Journal of Oncology CrossRef
8. In Silico Evaluation of Two Targeted Chimeric Proteins Based on Bacterial Toxins for Breast Cancer Therapy
   Zoleikha Goleij et al, 2019, International Journal of Cancer Management CrossRef
9. Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review
   Mattia Lunardi et al, 2022, BMC Cancer CrossRef
10. Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
    Sandra Cotino-Nájera et al, 2023, Frontiers in Pharmacology CrossRef
11. A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients
    Xinna Zhou et al, 2015, SpringerPlus CrossRef
12. Development of a Novel Anti-HER2 Monoclonal Antibody H2Mab-181 for Gastric Cancer
    Junko Takei et al, 2021, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
13. Biomarkers in Breast Carcinomas
    Yasemin Sahin et al, 2022, Biomarkers in Carcinoma of Unknown Primary CrossRef
14. A Retrospective Analysis of Biosimilar and Reference Trastuzumab in Human Epidermal Growth Factor Receptor-2 Positive Early and/or Locally Advanced Breast Cancer Patients Treated with Neoadjuvant-Adjuvant Setting
    Rahul Kulkarni et al, 2021, Oncology Journal of India CrossRef
15. In Silico Designing a Candidate Vaccine Against Breast Cancer
    Amir Atapour et al, 2020, International Journal of Peptide Research and Therapeutics CrossRef
16. The Notch Pathway in Breast Cancer Progression
    Emmanuel N. Kontomanolis et al, 2018, The Scientific World Journal CrossRef
17. The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance
    Ajeya Nandi et al, 2020, Genes & Development CrossRef
18. Resistance to Intervention: Paclitaxel in Breast Cancer
    Vipin Mohan Dan et al, 2021, Mini-Reviews in Medicinal Chemistry CrossRef
19. Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition
    Monica E. Wielgos et al, 2018, Molecular Cancer Therapeutics CrossRef
20. A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
    Moudi M. Alasmari, 2022, Cancers CrossRef
21. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion
    Sangsu Park et al, 2021, International Journal of Molecular Sciences CrossRef
22. Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
    Stacy L. Moulder et al, 2017, Clinical Cancer Research CrossRef
23. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target
    Min Joung Lee et al, 2016, Journal of Cancer Research and Clinical Oncology CrossRef
24. IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src/STAT3/ERK1/2-mediated EGFR signaling
    Shaza Ahmed et al, 2021, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research CrossRef
25. Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction
    Adam Sharp et al, 2015, Case Reports in Oncology CrossRef
26. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer
    Yadollah Omidi et al, 2022, Journal of Drug Targeting CrossRef
27. The Role of Pharmacogenomics in Individualized Medicine
    Henriette E. Meyer zu Schwabedissen, 2015, Individualized Medicine CrossRef
28. A comparison of clinical–pathological characteristics between symptomatic and interval breast cancer
    B. Meshkat et al, 2015, The Breast CrossRef
29. Relatives of Crohn's disease patients and breast cancer: An overlooked condition
    Gianluca Pellino et al, 2014, International Journal of Surgery CrossRef
30. Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H2Mab-181) Using Enzyme-Linked Immunosorbent Assay
    Teizo Asano et al, 2021, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy CrossRef
31. Boesenbergia Pandurata as an Anti-Breast Cancer Agent: Molecular Docking and ADMET Study
    Mohammad Rizki Fadhil Pratama et al, 2022, Letters in Drug Design & Discovery CrossRef
32. Acalabrutinib as a novel hope for the treatment of breast and lung cancer: an in-silico proof of concept
    Kedar Khaparkhuntikar et al, 2024, Journal of Biomolecular Structure and Dynamics CrossRef
33. Current and emerging therapies in unresectable and recurrent gastric cancer
    Erin Jou et al, 2016, World Journal of Gastroenterology CrossRef
34. Recent advances in the HER2 targeted therapy of gastric cancer
    Tasuku Matsuoka, 2015, World Journal of Clinical Cases CrossRef
35. Hidden Markov Model-Based CNV Detection Algorithms for Illumina Genotyping Microarrays
    Eric L. Seiser et al, 2014, Cancer Informatics CrossRef
36. Feline Mammary Carcinoma: Past, Present and Future
    A. Gameiro et al, 2020, Advances in Animal Health, Medicine and Production CrossRef
37. A case of HER2 positive primary unknown adenocarcinoma with cervical lymph node metastasis detected by laryngeal edema
    Takuya Mikoshiba et al, 2016, JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY CrossRef
38. Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
    Soon Young Park et al, 2023, Cell Death & Disease CrossRef
39. Liposome-Based Drug Delivery—A New Therapeutic Paradigm
    Laukik Shetye et al, 2023, Advanced Drug Delivery CrossRef
40. Predicting cancer outcomes with radiomics and artificial intelligence in radiology
    Kaustav Bera et al, 2022, Nature Reviews Clinical Oncology CrossRef
41. In Silico Design and Evaluation of scFv-CdtB as a Novel Immunotoxin for Breast Cancer Treatment
    Asma Vafadar et al, 2020, International Journal of Cancer Management CrossRef
42. Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
    Maria T. Bourlon et al, 2016, Cancer Medicine CrossRef